Treatment of Parkinson's disease with PDGF
View Patent ↗The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells. These methods are useful for reducing at least one symptom of the disorder.
1. A method of treating a patient with Parkinson's disease or Parkinsonian disorders comprising administering PDGF-BB in vivo directly to the central nervous system of said patient, wherein the PDGF-BB is administered in an amount of between 0.5 ng/kg/day to 500 ng/kg/day.
2. A method for inducing the in situ proliferation or differentiation of neural stem cells or neural progenitor cells located in a neural tissue of a human, the method comprising administering an amount of PDGF-BB of between 0.5 ng/kg/day to 500 ng/kg/day, to the neural tissue to induce the proliferation or differentiation of the neural stem cells or neural progenitor cells.
3. A method of increasing the number of dopaminergic neurons in a patient suffering from Parkinson's disease or Parkinsonian disorders comprising the step of infusing the central nervous system of said patient with an amount of PDGF-BB of between 0.5 ng/kg/day to 500 ng/kg/day to increase the number of dopaminergic neurons.
4. The method of claim 1 wherein said method induces the differentiation, migration, proliferation or survival of neural stem cells or neural progenitor cell in said patient.
5. The method of claim 1 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.
6. The method of claim 2 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.
7. The method of claim 3 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.
8. A method of treating a patient with Parkinson's disease or Parkinsonian disorders comprising administering PDGF-BB in vivo directly to the central nervous system of said patient, wherein the PDGF-BB is administered in an amount of between 0.1 ng/kg/day to 1 μg/kg/day.
9. The method of claim 8 wherein said method induces the differentiation, migration, proliferation or survival of neural stem cells or neural progenitor cell in said patient.
10. The method of claim 8 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.
11. A method for inducing the in situ proliferation or differentiation of neural stem cells or neural progenitor cells located in a neural tissue of a human, the method comprising administering an amount of PDGF-BB of between 0.1 ng/kg/day to 1 μg/kg/day, to the neural tissue to induce the proliferation or differentiation of the neural stem cells or neural progenitor cells.
12. The method of claim 11 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.
13. A method of increasing the number of dopaminergic neurons in a patient suffering from Parkinson's disease or Parkinsonian disorders comprising the step of infusing the central nervous system of said patient with an amount of PDGF-BB of between 0.1 ng/kg/day to 1 μg/kg/day to increase the number of dopaminergic neurons.
14. The method of claim 13 wherein said PDGF-BB is administered intracerebroventricularly, intraparenchymally, intrathecally, intracranially or nasally.